These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
108 related articles for article (PubMed ID: 21103860)
1. Supratherapeutic oseltamivir levels during continuous dialysis: an expected risk. Eschenauer GA; Lam SW Intensive Care Med; 2011 Feb; 37(2):371. PubMed ID: 21103860 [No Abstract] [Full Text] [Related]
2. Pharmacokinetics of oseltamivir and oseltamivir carboxylate in critically ill patients receiving continuous venovenous hemodialysis and/or extracorporeal membrane oxygenation. Eyler RF; Heung M; Pleva M; Sowinski KM; Park PK; Napolitano LM; Mueller BA Pharmacotherapy; 2012 Dec; 32(12):1061-9. PubMed ID: 23208833 [TBL] [Abstract][Full Text] [Related]
3. [Can oseltamivir (Tamiflu) be used in dialysis-requiring renal failure?]. Rosenborg S Lakartidningen; 2010 Jan 20-26; 107(3):116-7. PubMed ID: 20225688 [No Abstract] [Full Text] [Related]
4. Oseltamivir carboxylate accumulation in a patient treated by haemodiafiltration and extracorporeal membrane oxygenation. Lemaitre F; Luyt CE; Roullet-Renoleau F; Nieszkowska A; Zahr N; Fernandez C; Farinotti R; Combes A Intensive Care Med; 2010 Jul; 36(7):1273-4. PubMed ID: 20376428 [No Abstract] [Full Text] [Related]
5. Oseltamivir dosing in children undergoing hemodialysis. Schreuder MF; van der Flier M; Knops NB; Koster-Kamphuis L; Brüggemann RJ Clin Infect Dis; 2010 May; 50(10):1427-8. PubMed ID: 20397934 [No Abstract] [Full Text] [Related]
6. Pharmacokinetics of oseltamivir: an oral antiviral for the treatment and prophylaxis of influenza in diverse populations. Davies BE J Antimicrob Chemother; 2010 Apr; 65 Suppl 2(Suppl 2):ii5-ii10. PubMed ID: 20215135 [TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics and dosage adjustment of oseltamivir and zanamivir in patients with renal failure. Karie S; Launay-Vacher V; Janus N; Izzedine H; Deray G Nephrol Dial Transplant; 2006 Dec; 21(12):3606-8. PubMed ID: 16799172 [No Abstract] [Full Text] [Related]
8. Oseltamivir and its active metabolite cross the placenta at significant levels. Meijer WJ; Bruinse HW; van den Broek MP; Kromdijk W; Wensing AM Clin Infect Dis; 2012 Jun; 54(11):1676-7. PubMed ID: 22460968 [No Abstract] [Full Text] [Related]
9. Oseltamivir dosing in premature infants. McPherson C; Warner B; Hunstad DA; Elward A; Acosta EP J Infect Dis; 2012 Sep; 206(6):847-50. PubMed ID: 22807525 [TBL] [Abstract][Full Text] [Related]
13. Interaction between oseltamivir and herbal medicines used for treating avian influenza. Yang MS; Law FC; Wong RN; Mak NK; Wei XY Hong Kong Med J; 2012 Dec; 18 Suppl 6():34-6. PubMed ID: 23249852 [No Abstract] [Full Text] [Related]
14. Pharmacokinetics of Oral and Intravenous Oseltamivir Treatment of Severe Influenza B Virus Infection Requiring Organ Replacement Therapy. Karsch K; Chen X; Miera O; Peters B; Obermeier P; Francis RC; Amann V; Duwe S; Fraaij P; Heider A; de Zwart M; Berger F; Osterhaus A; Schweiger B; Rath B Eur J Drug Metab Pharmacokinet; 2017 Feb; 42(1):155-164. PubMed ID: 26994602 [TBL] [Abstract][Full Text] [Related]
15. Transplacental transfer of oseltamivir and its metabolite using the human perfused placental cotyledon model. Berveiller P; Mir O; Vinot C; Bonati C; Duchene P; Giraud C; Gil S; Treluyer JM Am J Obstet Gynecol; 2012 Jan; 206(1):92.e1-6. PubMed ID: 21958869 [TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics and safety of intravenous oseltamivir in infants and children in open-label studies. Muñoz FM; Anderson EJ; Deville JG; Clinch B; Kamal MA Int J Clin Pharmacol Ther; 2015 Jul; 53(7):531-40. PubMed ID: 26042486 [TBL] [Abstract][Full Text] [Related]
17. Plasma concentrations of oseltamivir and oseltamivir carboxylate in critically ill children on extracorporeal membrane oxygenation support. Wildschut ED; de Hoog M; Ahsman MJ; Tibboel D; Osterhaus AD; Fraaij PL PLoS One; 2010 Jun; 5(6):e10938. PubMed ID: 20532176 [TBL] [Abstract][Full Text] [Related]
18. Lack of unwanted effects of oseltamivir carboxylate in juvenile rats after subcutaneous administration. Freichel C; Breidenbach A; Gand L; Toot J; Weiser T; Körner A; Singer T; Prinssen E; Hoffmann G Basic Clin Pharmacol Toxicol; 2012 Jun; 110(6):551-3. PubMed ID: 22145997 [No Abstract] [Full Text] [Related]
20. Active metabolite from Tamiflu solution is bioequivalent to that from capsule delivery in healthy volunteers: a cross-over, randomised, open-label study. Brewster M; Smith JR; Dutkowski R; Robson R Vaccine; 2006 Nov; 24(44-46):6660-3. PubMed ID: 16797800 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]